[go: up one dir, main page]

MX2015005252A - Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1. - Google Patents

Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.

Info

Publication number
MX2015005252A
MX2015005252A MX2015005252A MX2015005252A MX2015005252A MX 2015005252 A MX2015005252 A MX 2015005252A MX 2015005252 A MX2015005252 A MX 2015005252A MX 2015005252 A MX2015005252 A MX 2015005252A MX 2015005252 A MX2015005252 A MX 2015005252A
Authority
MX
Mexico
Prior art keywords
novel method
cardiac infarction
treating cardiac
hmgb1 fragment
fragment
Prior art date
Application number
MX2015005252A
Other languages
English (en)
Other versions
MX361259B (es
Inventor
Katsuto Tamai
Sokichi Kamata
Yasufumi Kaneda
Shigeru Miyagawa
Yoshiki Sawa
Takehiko Yamazaki
Original Assignee
Genomix Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomix Co Ltd filed Critical Genomix Co Ltd
Publication of MX2015005252A publication Critical patent/MX2015005252A/es
Publication of MX361259B publication Critical patent/MX361259B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un fragmento de péptido que tiene una longitud apropiada compuesta de una parte de una proteína de HMGB1 fue sintetizada y se confirmó que el péptido muestra efectos terapéuticos en el infarto al miocardio.
MX2015005252A 2012-10-25 2013-10-24 Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio. MX361259B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012235785 2012-10-25
PCT/JP2013/078758 WO2014065347A1 (ja) 2012-10-25 2013-10-24 Hmgb1断片を利用した新規心筋梗塞の治療法

Publications (2)

Publication Number Publication Date
MX2015005252A true MX2015005252A (es) 2015-10-29
MX361259B MX361259B (es) 2018-11-30

Family

ID=50544720

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005252A MX361259B (es) 2012-10-25 2013-10-24 Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.

Country Status (17)

Country Link
US (1) US9623078B2 (es)
EP (1) EP2913058B1 (es)
JP (1) JP6253589B2 (es)
KR (1) KR102146815B1 (es)
CN (1) CN104884076B (es)
AU (1) AU2013335684B2 (es)
BR (1) BR112015009037A2 (es)
CA (1) CA2889275C (es)
DK (1) DK2913058T3 (es)
ES (1) ES2660420T3 (es)
HK (2) HK1211488A1 (es)
MX (1) MX361259B (es)
PL (1) PL2913058T3 (es)
RU (1) RU2647467C2 (es)
SG (1) SG11201503236RA (es)
TR (1) TR201802122T4 (es)
WO (1) WO2014065347A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571230C2 (ru) 2008-04-30 2015-12-20 Дженомикс Ко., Лтд. Способ сбора функциональных клеток in vivo с высокой эффективностью
RU2016135937A (ru) 2009-10-28 2018-12-11 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
WO2012147470A1 (ja) 2011-04-26 2012-11-01 株式会社ジェノミックス 組織再生を誘導するためのペプチドとその利用
PL2913058T3 (pl) 2012-10-25 2018-04-30 Genomix Co., Ltd. Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1
PL2913059T3 (pl) 2012-10-25 2018-09-28 Genomix Co., Ltd. Nowy sposób leczenia urazu rdzenia kręgowego z zastosowaniem fragmentu HMGB1
CN110494154B (zh) * 2017-01-27 2023-09-29 斯特姆里姆有限公司 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂
US20200038486A1 (en) * 2017-04-07 2020-02-06 StemRIM Inc. Therapeutic medicine for fibrous disease
SG11201909851SA (en) * 2017-04-25 2019-11-28 Shionogi & Co Peptide for inducing regeneration of tissue, and use thereof
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
WO2020071520A1 (ja) * 2018-10-05 2020-04-09 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
KR20210082478A (ko) 2018-10-25 2021-07-05 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 연골 질환의 치료약
KR20220137876A (ko) 2019-11-12 2022-10-12 옥스포드 유니버시티 이노베이션 리미티드 조직 재생의 촉진에 유용한 hmgb1과 관련된 폴리펩티드, 이를 포함하는 조성물, 및 이들의 용도
RU2718912C1 (ru) * 2019-12-24 2020-04-15 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт общей патологии и физиологии" (ФГБНУ "НИИОПП") Способ лечения и профилактики инфаркта миокарда с патологией легких
US20230173027A1 (en) * 2020-04-20 2023-06-08 Shionogi & Co., Ltd. Formulation containing hmgb1 partial peptide
WO2022243932A1 (en) 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
WO2024005133A1 (ja) * 2022-06-30 2024-01-04 国立大学法人大阪大学 半月板の治療薬

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5238680B2 (es) 1972-12-27 1977-09-30
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6720340B1 (en) 1999-07-28 2004-04-13 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine receptor agonists in stem cell and progenitor cell recruitment
EP1114862A3 (de) 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
EP1257632B1 (en) 2000-02-24 2007-09-12 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP3421741B2 (ja) 2000-05-18 2003-06-30 筑波大学長 人工骨髄、血球細胞の増殖方法
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
DE10121254A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
AU2002304710A1 (en) 2001-04-30 2002-11-11 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
US20030060410A1 (en) 2001-05-15 2003-03-27 North Shore Long Island Jewish Research Institute Use of HMG fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
JPWO2003043651A1 (ja) 2001-11-19 2005-03-10 協和醗酵工業株式会社 多分化能幹細胞を組織から末梢血へ動員する薬剤
CA2849201A1 (en) 2001-12-07 2003-07-03 Macropore Biosurgery, Inc. Adipose-derived cell processing unit
RU2005102593A (ru) * 2002-07-03 2005-10-10 Фондационе Чентро Сан Раффаэле Дель Монте Табор (It) Применение hmgb1 при лечении повреждения ткани и/или для промотирования восстановления ткани
WO2004004770A1 (en) 2002-07-05 2004-01-15 Universite Laval Chemotactic factor inhibitor for modulating inflammatory reactions
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1569684A4 (en) 2002-11-20 2006-08-02 Critical Therapeutics Inc USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
JP2006517537A (ja) 2003-01-03 2006-07-27 アルケド バイオテック ゲーエムベーハー Ｄｎａ結合タンパク質の使用
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
ATE411038T1 (de) 2003-03-28 2008-10-15 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
US20050014255A1 (en) 2003-05-29 2005-01-20 Board Of Regents, The University Of Texas System Stem cells for clinical and commercial uses
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
WO2006008779A1 (en) 2004-07-20 2006-01-26 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione-Istituto Dermopatico Dell'immacolata Use of hmgb1 for wound healing
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
NZ553809A (en) 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
ITRM20050032A1 (it) 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
JP5103626B2 (ja) 2005-01-27 2012-12-19 財団法人ヒューマンサイエンス振興財団 間葉系幹細胞を含む細胞シート
ES2345837T3 (es) 2005-03-23 2010-10-04 Biosafe S.A. Sistema integrado para la recogida, el procesamiento y el trasplante de subgrupos de celulas, incluyendo celulas madre adultas, para medicina regenerativa.
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
WO2007015546A1 (ja) 2005-08-04 2007-02-08 Genomix Co., Ltd 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
WO2007031100A1 (en) 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
JP4982739B2 (ja) 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 ポリグルタミン病の予防・治療剤
ES2396220T3 (es) 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
US20090202500A1 (en) 2006-10-30 2009-08-13 Genomix Co., Ltd. Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues
CA2722852A1 (en) 2008-04-30 2009-11-05 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
WO2009133940A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
RU2571230C2 (ru) 2008-04-30 2015-12-20 Дженомикс Ко., Лтд. Способ сбора функциональных клеток in vivo с высокой эффективностью
CA2777663A1 (en) 2009-10-16 2011-04-21 University Of Medicine And Dentistry Of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
RU2016135937A (ru) 2009-10-28 2018-12-11 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
WO2012147470A1 (ja) 2011-04-26 2012-11-01 株式会社ジェノミックス 組織再生を誘導するためのペプチドとその利用
CN102443064A (zh) * 2011-11-03 2012-05-09 刘誉 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用
PL2913059T3 (pl) 2012-10-25 2018-09-28 Genomix Co., Ltd. Nowy sposób leczenia urazu rdzenia kręgowego z zastosowaniem fragmentu HMGB1
PL2913058T3 (pl) 2012-10-25 2018-04-30 Genomix Co., Ltd. Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1

Also Published As

Publication number Publication date
US9623078B2 (en) 2017-04-18
HK1212887A1 (zh) 2016-06-24
BR112015009037A2 (pt) 2017-11-14
KR102146815B1 (ko) 2020-08-21
AU2013335684A1 (en) 2015-05-14
SG11201503236RA (en) 2015-06-29
RU2015119517A (ru) 2016-12-20
JP6253589B2 (ja) 2017-12-27
ES2660420T3 (es) 2018-03-22
US20150273017A1 (en) 2015-10-01
TR201802122T4 (tr) 2018-03-21
JPWO2014065347A1 (ja) 2016-09-08
CA2889275A1 (en) 2014-05-01
CN104884076B (zh) 2017-10-03
CN104884076A (zh) 2015-09-02
EP2913058A1 (en) 2015-09-02
EP2913058B1 (en) 2017-12-20
AU2013335684B2 (en) 2017-06-29
RU2647467C2 (ru) 2018-03-15
DK2913058T3 (en) 2018-02-19
KR20150103660A (ko) 2015-09-11
HK1211488A1 (en) 2016-05-27
PL2913058T3 (pl) 2018-04-30
MX361259B (es) 2018-11-30
CA2889275C (en) 2021-06-15
EP2913058A4 (en) 2016-04-13
WO2014065347A1 (ja) 2014-05-01

Similar Documents

Publication Publication Date Title
MX2015005252A (es) Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
HK1208151A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer 182
MX2015005253A (es) Metodo novedoso para tratar el daño a la medula espinal utilizando el fragmento de hmgb1.
DK3791896T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
MY181969A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
SG10201903119QA (en) Polypeptide vaccine
MX2024008826A (es) Composicion para la estimulacion ovarica controlada.
BR112016018170A2 (pt) métodos para tratar doença de alzheimer
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
MX2017000306A (es) Metodos para tratar hipotension.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
RS63738B1 (sr) Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
MX2020005454A (es) Tratamiento de cancer mejorado.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
UA61938U (ru) СПОСОБ ЛЕЧЕНИЯ больных с болевымИ нейрокомпрессионныМИ спондилогенныМИ СИНДРОМАМИ

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: KUMIAI CHEMICAL INDUSTRY CO., LTD.